Loading…
Loading…
EQUITY / NASDAQ · XNCM
Relmada Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗3.6 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 3.6 USD · Volume 1,209,553
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -15,011,027 USD | -10,221,306 USD | — |
| Net income | -12,914,185 USD | -9,866,442 USD | — |
| Cash and cash equivalents | 11,334,370 USD | — | — |
| Total liabilities | 12,500,854 USD | — | — |
| Total equity | 206,558,323 USD | 15,949,481 USD | +1,195.08% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 11,334,370 USD | — | — | 3,496,540 USD | 3,496,540 USD | 1,384,484 USD | — | — |
| Net incomeIncome statement | -12,914,185 USD | -31,966,141 USD | -19,051,956 USD | — | -57,385,163 USD | -10,091,496 USD | -37,517,403 USD | -9,866,442 USD |
| Operating profitIncome statement | -15,011,027 USD | -34,472,781 USD | — | — | -59,100,200 USD | -10,327,346 USD | -38,767,088 USD | -10,221,306 USD |
| Total assetsBalance sheet | 219,059,177 USD | — | — | 94,003,471 USD | 94,003,471 USD | 14,876,244 USD | — | — |
| Total equityBalance sheet | 206,558,323 USD | — | 218,732,577 USD | 86,512,013 USD | 86,512,013 USD | 9,465,539 USD | — | 15,949,481 USD |
| Total liabilitiesBalance sheet | 12,500,854 USD | — | — | 7,491,458 USD | 7,491,458 USD | 5,410,705 USD | — | — |
| Financing cash flowCash flow statement | — | 150,153,362 USD | — | — | 93,564,808 USD | — | -73,021 USD | — |
| Investing cash flowCash flow statement | — | -117,641,611 USD | — | — | -48,138,306 USD | — | 28,791,244 USD | — |
| Operating cash flowCash flow statement | — | -24,673,921 USD | — | — | -45,786,988 USD | — | -31,190,765 USD | — |
| Report source | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 03/19/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 08/06/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.